Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846744 | 0.84 | NR4A2 (0.57) | NPC1RAB9AKMT2ANR4A2NR1H4 | |
| SCHEMBL6841240 | 0.83 | MEN1 (0.47) | SMPD1NPC1RAB9AMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6841319 | 0.82 | NR4A2 (0.56) | NPC1RAB9AKMT2ANR4A2 | |
| SCHEMBL6848196 | 0.81 | CYSLTR1 (0.58) | NPC1RAB9AMEN1KMT2ANR4A2 | |
| SCHEMBL6841241 | 0.80 | CYSLTR1 (0.43) | SMPD1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL7550926 | 0.78 | CYSLTR1 (0.42) | SMPD1NPC1RAB9AKMT2ANR4A2 | |
| SCHEMBL6845358 | 0.77 | NPC1 (0.47) | NPC1RAB9AMEN1KMT2ANR1H4 | |
| SCHEMBL6846538 | 0.76 | ATM (0.48) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6846907 | 0.76 | BRAF (0.49) | NPC1RAB9AMEN1KMT2ANR1H4 | |
| SCHEMBL6846623 | 0.76 | GPR132 (0.45) | NPC1RAB9AMEN1KMT2ANR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | claimed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | claimed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | claimed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | claimed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | SMPD1 1129/4885NPC1 4543/4885RAB9A 1183/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | SMPD1 1129/4885NPC1 4543/4885RAB9A 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.